Management of cancer-associated thrombosis in people with advanced disease
- 1Department of Palliative Medicine, Cardiff University, Newport, UK
- 2Department of Health Sciences, Hull York Medical School, Scarborough, UK
- Correspondence to Dr Simon Noble, Department of Palliative Medicine, Cardiff University, Newport, UK;
Contributors SN and MJJ both conceived the idea for the paper and co-authored the paper together.
The management of venous thromboembolism in the cancer population is clearly established. Low molecular weight heparin has a greater efficacy than warfarin in the treatment of cancer-associated thrombosis and is recommended as the preferred therapy. However, the evidence informing these recommendations excluded patients with poor prognosis or performance status, thrombocytopenia, bleeding or brain metastases. Furthermore, there is limited data on the management of venous thromboembolism resistant to anticoagulation, a phenomenon frequently encountered in the advanced cancer population. This paper will review the management of cancer-associated thrombosis with a particular focus on challenging clinical situations faced by palliative care teams looking after patients with advanced disease.
Competing interests None.
Provenance and peer review Not commissioned; externally peer reviewed.
- Received 4 November 2011.
- Accepted 21 January 2012.
- Published Online First 29 February 2012
- Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions